Carpmaels & Ransford LLP > London, England > Firm Profile

Carpmaels & Ransford LLP
ONE SOUTHAMPTON ROW
LONDON
WC1B 5HA
England

TMT (technology, media and telecoms) > PATMA: Patent attorneys Tier 1

Carpmaels & Ransford LLP has a strong reputation in the healthcare sector, frequently assisting clients with EPO oppositions, prosecutions, and litigation on a domestic and pan-European scale. Managing partner Hugh Goodfellow is a notable member of the team with significant expertise in representing both well-established and growing biotechnology companies in prosecution proceedings. Head of the engineering and technology groups John Brunner is highly experienced in EPO oppositions, while James Warner leads the chemistry and pharmaceuticals departments with extensive knowledge in prosecution and defence proceedings in these sectors. The biotechnology team is spearheaded by Mark Chapman, and he specialises in antisense therapeutics, antibody therapeutics, and immunomodulatory therapies. Jake Marshall heads up the intellectual property transactions department.

Practice head(s):

Hugh Goodfellow; John Brunner; James Warner; Mark Chapman; Jake Marshall

Other key lawyers:

Harvey Adams; Cameron Marshall; Daniel Wise; Edward Oates; Paul Bettridge; Matthew Georgiou; Stephen Duffield; Anna Leathley; Chris Hoggett; Daiel Goodman; Ian Kirby

Testimonials

‘Biotech, knowledge of the field, excellent understanding of the subject, easy to approach, and fast service. To date, all patent cases have been won when challenged in court.’

‘Very helpful and friendly, often making excellent suggestions.’

‘The attorneys I’ve worked with at Carpmaels are fantastic! I would recommend this firm to anyone looking for EP patent counsel.’

‘The diverse team of attorneys with whom I have had the pleasure of working are driven, smart, and willing to go the extra mile. They think about the strategy based on the goals of the company. They never just do something because it gets something allowed; they always consider the value.’

‘In both prosecution and oppositions, they come prepared to discuss the strategy in view of the company goals, not just the single patent on which we are working. They have already considered many different scenarios and are willing to walk through the pros and cons of each. They have a recommendation, but are willing to alter it depending on the facts.’

‘The team works together well so that nothing is lost if someone cannot attend a call etc. The trust they have in each other shines when walking through strategy and how best to leverage what we have in hand. As the associates get more senior the team recognises when more junior people should come on and assist with the portfolio.’

‘They are never caught on their back foot. Without question, this is a team I would seek out to work with again and again.’

Key clients

Abbott

Acorda Therapeutics

Afiniti, Ltd.

Align Technology Inc

Amgen

AMO Development LLC

Auris Health

Verb Surgical

Barclays Bank Plc

Biogen Inc.

Biosense Webster

Bozicevic, Field & Francis LLP

Bristol Myers Squibb

CSL

Dupont Teijin Films

Ethicon

Genus

Gilead

Guardant Health Inc

Hub Organoids

Hypertherm

Imperial Brands

Incyte

Ionis Pharmaceuticals

Ipsen/Servier

Janssen Pharmaceuticals

Jazz Pharmaceuticals

Johnson & Johnson

Juno

LEO Pharma

LifeScan, Inc.

McNeil AB

Merck

Novartis

Novocure

Quantum – Si

Raytheon Technologies Corporation

Regeneron

Roche

Rondo Energy

Sanofi

Takeda

Vertex

Work highlights

  • Representing Sanofi & Regeneron in a long-running project involving EPO patent prosecution, EPO oppositions, national litigation support, and, most recently, UPC litigation relating to Praluent® anti-PCSK9 antibody product and Amgen’s competing Repatha® product.
  • Represented Novartis AG in Enlarged Board of Appeal cases G1/22 and G2/22, in particular at the in-person hearing in May 2023, having previously persuaded the Technical Board of Appeal to refer questions to the EBA regarding important questions about entitlement to priority.
  • Represented multiple clients as opponents in opposition proceedings against Amgen’s patent that broadly claimed BCMAxCD3 bispecific antibodies.

TMT (technology, media and telecoms) > Intellectual property: patents (contentious and non-contentious) Tier 2

Recommended for its ‘strong industry knowledge’, Carpmaels & Ransford LLP is well-known for its ability to advise healthcare and life sciences clients in EPO oppositions, strategic prosecutions, and patent and SPC litigation. The practice is jointly led by David Wilson, who is entrusted by science and technology players to assist with multi-jurisdictional litigation, Hugh Goodfellow, and Jake Marshall, who helms the transactional group with his expertise in IP and technology. Other key names to note in the practice include Camilla Balleny, who is well-versed in patent litigation as well as advisory work, and Ian Kirby, whose arsenal of skills encompass monoclonal antibodies and voice recognition technologies, among others. Jennifer Antcliff enjoys considerable litigation experience, having represented clients in the High Court, Court of Appeal, and Supreme Court. Craig Lumb is also recommended.

Practice head(s):

David Wilson; Hugh Goodfellow; Jake Marshall

Other key lawyers:

Camilla Balleny; Ian Kirby; Jake Marshall; Jennifer Antcliff; Simon Llewellyn; Agathe Michelde Cazotte; Craig Lumb

Testimonials

‘The Carpmaels team has strong industry knowledge and does a great job integrating litigators with the patent attorney team.’

‘David Wilson is a strong leader.’

‘Very well-supported IP team with the patent prosecution back up.’

‘Ian Kirby is an excellent leader.’

Key clients

Sanofi-Aventis

Johnson & Johnson group

FibroGen, Inc.

Novartis

AMO Development, LLC

Takeda

Regeneron Pharmaceuticals, Inc.

Bristol Myers Squibb

Sidley Austin

Work highlights

  • Representing Sanofi & Regeneron and Amgen in handling a long-running project involving EPO patent prosecution, EPO oppositions, national litigation support, and most recently UPC litigation relating Sanofi & Regeneron’s Praluent® anti-PCSK9 antibody product and Amgen’s competing Repatha® product.
  • Representing Johnson & Johnson in defending and enforcing its patents that protect their biggest product, Stelara, which is a biological product used in the treatment of autoimmune diseases.
  • Assisting Janssen with the revocation of certain antibody patents owned by Amgen at the EPO and in the UK, to clear the way for the launch of its product, TECVAYLI, Janssen’s first-in-class bispecific antibody therapy for treating multiple myeloma, an incurable blood cancer.

TMT (technology, media and telecoms) > PATMA: Trade mark attorneys Tier 2

Roger Lush sits at the helm of the trade marks practice at Carpmaels & Ransford LLP, which handles the entire lifecycle of mandates, from clearance searches and registration, to enforcement, disputes, litigation, and licensing, as well as contractual and transactional matters. The team also frequently represents clients before the UKIPO, EUIPO, and WIPO. Industries in which the team is especially active include the entertainment and sports, healthcare, luxury brands, consumer goods, and technology sectors, among others. Jonathan Day is dual qualified as a trade mark attorney and solicitor and he supports clients with anti-counterfeiting matters and enforcement strategies. Lara Elder is another notable name in trade mark infringement and passing off cases.

Practice head(s):

Roger Lush

Other key lawyers:

Key clients

Align Technology, Inc.

Bear Grylls Ventures LLP

Manzanita Capital

Allergan (BOTOX®)/AbbVie

Deere & Company

Crosta & Mollica

Blue Prism

Western Digital

Byredo

Diptyque

Space NK

XEROS

Eyeora

Penguin Random House

Converge

Motorsport UK

Vertex

Umarex GmbH

Republic Technologies

4D Pharma

Aphria

OTCX Trading

De Beers

Malin + Goetz

Altery

Susanne Kaufmann

Iris Nation

McArthurGlen

Belron

Antler

McIlhenny Company

Western Digital

TotalEnergies

GAM Limited

Veld Capital

Anacap Financial Partners

Kalvista

Fomtech Limited

Deep Research Labs

D.S. & Durga

Incyte

Secqai Limited

Azaries Limited

Work highlights

  • Advising Allergan/AbbVie on all matters, from brand counselling and clearance, filing and prosecution, through to opposition, cancellation, and enforcement and dispute resolution.
  • Assisting Bear Grylls Ventures with the expansion and defence of the Bear Grylls brand, including general counselling, portfolio management and prosecution of brand extension related filings pursuant to commercial partnerships and licence agreements.
  • Representing Deere & Company in the protection and enforcement of its iconic brands in the UK, including the Leaping Deere logo and yellow/green vehicle livery and associated colour-per-se marks.

Industry focus > Life sciences and healthcare Tier 4

EPO opposition, strategic prosecution, and patent and SPC litigation are core pillars of the ‘very strong’ team at Carpmaels & Ransford LLP. David Wilson leads the firm’s dispute resolution team and has a proven track record in negotiating high-value licenses and settlement agreements. James Warner is noted for his adept handling of multi-opponent EPO opposition proceedings. IP transactions specialist Jake Marshall is singled out for his expertise in commercial agreements. Camilla Balleny frequently brings her contentious IP experience to bear on SPC and divisional filing strategies.

Practice head(s):

Hugh Goodfellow; David Wilson; James Warner; Jake Marshall; Mark Chapman; Roger Lush

Other key lawyers:

Camilla Balleny; Edward Oates; Cameron Marshall; Daniel Wise; Harvey Adams; Jennifer Antcliff; Stephen Duffield; Simon Llewellyn; Agathe Michel-de Cazotte; Daniel Goodman; Paul Kaufman; Craig Lumb; Aled Richards-Jones

Testimonials

‘Carpmaels has strong industry knowledge and effectively integrates their litigators and patent attorneys.’

‘Aled Richards-Jones is a rising star who has excellent strategic judgment.’

‘Very strong team. Great depth and knowledge.’

‘Highly talented partners such as Edward Oates, Paul Kaufmann, Jennifer Antcliff and many others.’

‘The team are very experienced and can plan an effective overall strategy for a case.’

‘Harvey Adams has a great understanding and knowledge of long-running cases.’

‘The diverse team attorneys with whom I have had the pleasure of working are driven, smart, and willing to go the extra mile. They think about the strategy based on the goals of the company. They never just do something because it gets something allowed – they always consider the value.’

‘In both prosecution and oppositions, they come prepared to discuss the strategy in view of the company goals, not just the single patent on which we are working. They have already considered many different scenarios and are willing to walk through the pros and cons of each.’

Key clients

Sanofi-Aventis

Johnson & Johnson group, including various Janssen entities

FibroGen, Inc.

AMO Development, LLC (part of the Johnson & Johnson group)

Novartis

Takeda

Regeneron Pharmaceuticals, Inc.

Sidley Austin

Work highlights

  • Instructed to help defend and enforce the patents that protect Johnson & Johnson’s biggest product, Stelara.
  • Instructed by Janssen to revoke certain antibody patents (owned by Amgen) at the EPO and in the UK, to clear the way for the launch of its product, TECVAYLI.

Carpmaels & Ransford LLP is a leader in the European IP market, having driven innovation in the industry for over 200 years. The firm advises clients on all aspects of intellectual property including drafting, filing and prosecuting patent and trade mark applications, drafting and negotiating licence agreements and other commercial IP agreements, advising on the transfer of property rights, assisting clients with patent restoration matters and conducting enforcement and revocation litigation. 

The firm has one of Europe’s largest intellectual property teams serving blue-chip clients across the globe. The firm’s attorneys have considerable technical knowledge, bringing together experience from industry-leading companies, academic research at leading universities, and extensive patent expertise in the areas of engineering and tech, chemistry and materials, pharmaceuticals, biotechnology, supplementary protection certificates and information communications technology and standards. 

Through the firm’s fully integrated Dispute Resolution and Transactions teams, the firm is able to provide a holistic service for clients which supports their IP needs from inception to commercialisation. The Dispute Resolution team, comprised of experienced solicitors, barristers and patent attorney litigators, represents clients at all levels of the European Patent Office (EPO).The team is also adept at conducting enforcement litigation and revocation actions before the UK Intellectual Property Office (UKIPO) and patent, copyright, trade mark and other IP litigation in the English courts and the Court of Justice of the European Union. Carpmaels & Ransford is one of the few firms that can use the same team to handle parallel disputes in the EPO, UPC, and UK courts, while also coordinating national actions across Europe. The firm is perfectly positioned to represent clients at the UPC and is leading the first revocation action at the new court.   

As well as advising on the acquisition and licensing of IP rights, and other IP focused agreements, (such as development and collaboration agreements), the Transactions Team manages multi-jurisdictional patent/trade mark assignment recordal projects, provides specialist advice on the transfer of priority rights and assists clients with the restoration of registered IP rights around the world. 

Department Name Email Telephone
Managing partner Hugh Goodfellow
Chemistry and Pharmaceuticals Matthew Georgiou
Dispute resolution Ian Kirby
Engineering and technology John Brunner
Biotechnology Mark Chapman
Trade marks Roger Lush
Transactions Jake Marshall
Photo Name Position Profile
Harvey Adams photo Harvey Adams Harvey is a Partner focussing on the Life Sciences and Chemistry sectors.…
Jennifer Antcliff photo Jennifer Antcliff Jenny is a partner in the firm’s Dispute Resolution team, ranked as…
Isobel Barry photo Isobel Barry Isobel advises innovator healthcare companies through all stages of the therapeutic product…
Paul Bettridge photo Paul Bettridge Paul sits within our Engineering and Tech teams, predominantly working within the…
John Brunner photo John Brunner John has extensive experience assisting tech and healthcare companies in all aspects…
Mark Chapman photo Mark Chapman Mark leads the Biotechnology team at Carpmaels & Ransford. Mark’s impressive Biotech-only…
Bruce Cockerton photo Bruce Cockerton Bruce’s chemistry practice covers both industrial and medicinal chemistry, encompassing polymer chemistry,…
Jonathan Day photo Jonathan Day Jonathan is dual-qualified as a solicitor and trademark attorney. His background in…
Emma Demetriades photo Emma Demetriades Emma is a Partner in the Life Sciences team and her work…
Stephen Duffield photo Stephen Duffield Described as “simply a super patent attorney” (JUVE 2023), Stephen is a Partner in…
Matthew Georgiou photo Matthew Georgiou Matthew is the Practice Group Leader for the Chemistry and Pharmaceuticals group…
Hugh Goodfellow photo Hugh Goodfellow Hugh is the Managing Partner at Carpmaels & Ransford and a Partner…
Daniel Goodman photo Daniel Goodman Daniel covers a wide range of biotech inventions, including therapeutic antibodies, antisense…
Chris Hoggett photo Chris Hoggett Chris is a partner in the Pharmaceuticals team at Carpmaels & Ransford.…
David Holland photo David Holland David is a Partner in the Life Sciences group and has a…
Ben Husband  photo Ben Husband Ben has a considerable practice in the MedTech field which covers a…
Paul Kaufman photo Paul Kaufman Paul is a Partner in the Life Sciences team, specialising in small…
Ian Kirby photo Mr Ian Kirby Ian is a Partner in the Dispute Resolution team and focuses on…
Susan Kirsch photo Dr Susan Kirsch Susan is a Partner in the Chemistry team at Carpmaels & Ransford.…
Anna Leathley photo Anna Leathley Anna’s area of expertise is in biotech. She has a current focus…
Roger Lush photo Roger Lush Roger’s extensive and varied practice covers the full trade mark life-cycle, from…
Cameron Marshall photo Cameron Marshall Cameron focuses exclusively on the biotechnology and pharmaceutical fields, with an extensive…
Jake Marshall photo Jake Marshall Jake specialises in transactional and advisory matters involving intellectual property and technology.…
Edward Oates photo Edward Oates Ed built his “enviable track record” (IAM Patent 1000) on some of…
Gary Small photo Dr Gary Small Gary is a highly respected software, computer and medical technology specialist, who…
Annabel  Strawson photo Annabel Strawson Annabel qualified as a UK and European patent attorney in 2014. A…
James Warner photo James Warner James is a partner in the Life Sciences team and has over…
Natalia  Wegner  photo Natalia Wegner Natalia specialises in complex biotechnological subject matter, in particular cell and gene…
David Wilson photo David Wilson David is a partner in the Dispute Resolution team at Carpmaels &…
Daniel Wise photo Daniel Wise Daniel specialises in biologics and pharmaceuticals, with particular expertise in protein therapeutics,…
Photo Name Position Profile
Simon Llewellyn photo Simon Llewellyn Simon is a partner in the Dispute Resolution team whose practice focuses…
Number of UK partners : 31
Number of other UK fee-earners : 140

Carpmaels & Ransford team bolstered with Senior Associate promotions

Carpmaels & Ransford is pleased to announce Selina Badiani, Harry Bush, Emily Chittock, Henry Evans and Rebecca Satchwell have been promoted to Senior Associate positions effective from 1st January 2025.